WO2014165607A3 - Aromatic-cationic peptide formulations, compositions and methods of use - Google Patents

Aromatic-cationic peptide formulations, compositions and methods of use Download PDF

Info

Publication number
WO2014165607A3
WO2014165607A3 PCT/US2014/032701 US2014032701W WO2014165607A3 WO 2014165607 A3 WO2014165607 A3 WO 2014165607A3 US 2014032701 W US2014032701 W US 2014032701W WO 2014165607 A3 WO2014165607 A3 WO 2014165607A3
Authority
WO
WIPO (PCT)
Prior art keywords
aromatic
compositions
methods
cationic peptide
dmt
Prior art date
Application number
PCT/US2014/032701
Other languages
French (fr)
Other versions
WO2014165607A2 (en
Inventor
D. Travis WILSON
Original Assignee
Stealth Peptides International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International, Inc. filed Critical Stealth Peptides International, Inc.
Publication of WO2014165607A2 publication Critical patent/WO2014165607A2/en
Publication of WO2014165607A3 publication Critical patent/WO2014165607A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure relates to pharmaceutical compositions including an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2. In some embodiments, compositions described herein include a suspension, which comprises an admixture in solid form of a therapeutically effective amount of one or more aromaticcationic peptides such as D-Arg-2,6-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof, and optionally a therapeutically effective amount of one or more aromatic-cationic peptides. Pharmaceutical compositions have enhanced penetration across biological barriers. The present technology also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.
PCT/US2014/032701 2013-04-02 2014-04-02 Aromatic-cationic peptide formulations, compositions and methods of use WO2014165607A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361807685P 2013-04-02 2013-04-02
US61/807,685 2013-04-02
US201361809127P 2013-04-05 2013-04-05
US61/809,127 2013-04-05

Publications (2)

Publication Number Publication Date
WO2014165607A2 WO2014165607A2 (en) 2014-10-09
WO2014165607A3 true WO2014165607A3 (en) 2014-12-31

Family

ID=51659343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/032701 WO2014165607A2 (en) 2013-04-02 2014-04-02 Aromatic-cationic peptide formulations, compositions and methods of use

Country Status (1)

Country Link
WO (1) WO2014165607A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3080587C (en) 2008-09-17 2024-02-13 Chiasma Inc. Use of oral octreotride compositions
US9943563B2 (en) 2013-12-02 2018-04-17 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
GB2531742B (en) * 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol
WO2016144905A1 (en) 2015-03-06 2016-09-15 Stealth Biotherapeutics Corp Processes for preparing pharmaceutically relevant peptides
EA201892194A1 (en) * 2016-03-31 2019-04-30 Юнайтед Киндом Рисёрч Энд Инновейшн COMPOSITIONS OF THE COMPLEX OF A THREE VALVE IRON WITH A BALT FOR APPLICATION FOR THE TREATMENT OR PREVENTION OF CANCER AND TUMOR
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
US10993984B2 (en) * 2016-10-21 2021-05-04 Chiasma, Inc. Terlipressin compositions and their methods of use
WO2018111913A1 (en) * 2016-12-12 2018-06-21 Gi Dynamics, Inc. Methods for assessing treatment with a gastrointestinal implant
CN106727628A (en) * 2016-12-17 2017-05-31 郑州郑先医药科技有限公司 A kind of Western medicine compound for treating chronic diarrhea
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
KR102212226B1 (en) * 2017-12-21 2021-02-05 (주) 에이치엔에이파마켐 Composite for transdermal transfer using metal-organic framework and nanocellulose
CN109248152B (en) * 2018-11-02 2021-01-12 河北医科大学第二医院 A pharmaceutical preparation for treating liver and gallbladder diseases, and its preparation method
CN113795247B (en) * 2018-12-14 2024-04-05 陈益祥 Stable cardioplegia solution for cardiac surgery
CN115400201A (en) * 2021-05-26 2022-11-29 四川大学华西医院 Application of SS-31 in preparation of medicine for preventing and/or treating cigarette-induced airway inflammation and chronic obstructive pulmonary disease

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110722A1 (en) * 1999-05-27 2004-06-10 Ornberg Richard L. Modified hyaluronic acid polymers
US20040116657A1 (en) * 2001-03-01 2004-06-17 Flatt Peter Raymond Modified peptide
US20060159741A1 (en) * 2002-11-26 2006-07-20 Janez Kerc Pharmaceutical compositions comprising amoxicillin and clavulanic acid
US20060223752A1 (en) * 2000-06-28 2006-10-05 Langedijk Johannes P M Transport peptides such as C-terminal Erns peptide and analogues thereof
US20060251713A1 (en) * 2002-02-07 2006-11-09 Chiasma, Inc. Amino acid sequences capable of facilitating penetration across a biological barrier
US20090029910A1 (en) * 2006-02-09 2009-01-29 Novartis Ag Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
WO2012039596A2 (en) * 2010-09-22 2012-03-29 Craun Research Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20120093886A1 (en) * 2008-09-17 2012-04-19 Paul Salama Pharmaceutical compositions and related methods of delivery
US20120288531A1 (en) * 2011-01-14 2012-11-15 Shmuel Tuvia pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
US20130059784A1 (en) * 2010-03-15 2013-03-07 D. Travis Wilson Combination therapies using cyclosporine and aromatic cationic peptides

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110722A1 (en) * 1999-05-27 2004-06-10 Ornberg Richard L. Modified hyaluronic acid polymers
US20060223752A1 (en) * 2000-06-28 2006-10-05 Langedijk Johannes P M Transport peptides such as C-terminal Erns peptide and analogues thereof
US20040116657A1 (en) * 2001-03-01 2004-06-17 Flatt Peter Raymond Modified peptide
US20060251713A1 (en) * 2002-02-07 2006-11-09 Chiasma, Inc. Amino acid sequences capable of facilitating penetration across a biological barrier
US20060159741A1 (en) * 2002-11-26 2006-07-20 Janez Kerc Pharmaceutical compositions comprising amoxicillin and clavulanic acid
US20090029910A1 (en) * 2006-02-09 2009-01-29 Novartis Ag Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
US20120093886A1 (en) * 2008-09-17 2012-04-19 Paul Salama Pharmaceutical compositions and related methods of delivery
US20130059784A1 (en) * 2010-03-15 2013-03-07 D. Travis Wilson Combination therapies using cyclosporine and aromatic cationic peptides
WO2012039596A2 (en) * 2010-09-22 2012-03-29 Craun Research Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20120288531A1 (en) * 2011-01-14 2012-11-15 Shmuel Tuvia pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof

Also Published As

Publication number Publication date
WO2014165607A2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2017044894A3 (en) Cartilage-homing peptides
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2017194782A3 (en) Therapeutic targeting of non-cellular structures
MX2013005341A (en) Improved high concentration anti-tnfî± antibody liquid formulations.
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
IN2015DN00376A (en)
WO2013173129A3 (en) Treatment of amd using aav sflt-1
WO2017100700A3 (en) Peptides for renal therapy
EP3329965A3 (en) Dosing regimen of anti-alpha4beta7-antikörper
EP2528934A4 (en) Aromatic-cationic peptides and uses of same
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EA201490254A1 (en) COMBINED TREATMENT OF HEPATITIS C
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2014153160A3 (en) METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CeO2 PARTICLES VIA NANO-ENCAPSULATION AND COATING
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
WO2013085849A3 (en) Sulfate esters of noribogaine
EA201501054A1 (en) TREATMENT OF MYOPATHIES AND NEURODEGENERATIVE DISEASES ASSOCIATED WITH THE PROTECTION OF PROTEINS BY PARENTAL INTRODUCTION OF TRAGOSE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14779451

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01.02.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14779451

Country of ref document: EP

Kind code of ref document: A2